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Abstract
Immune responses against intestinal microbiota contribute to the pathogenesis of inflammatory bowel diseases (IBD) and
involve CD4+ T cells, which are activated by major histocompatibility complex class II (MHCII) molecules on antigen-
presenting cells (APCs). However, it is largely unexplored how inflammation-induced MHCII expression by intestinal
epithelial cells (IEC) affects CD4+ T cell-mediated immunity or tolerance induction in vivo. Here, we investigated how
epithelial MHCII expression is induced and how a deficiency in inducible epithelial MHCII expression alters susceptibility to
colitis and the outcome of colon-specific immune responses. Colitis was induced in mice that lacked inducible expression of
MHCII molecules on all nonhematopoietic cells, or specifically on IECs, by continuous infection with Helicobacter hepaticus
and administration of interleukin (IL)-10 receptor-blocking antibodies (anti-IL10R mAb). To assess the role of interferon (IFN)-
c in inducing epithelial MHCII expression, the T cell adoptive transfer model of colitis was used. Abrogation of MHCII
expression by nonhematopoietic cells or IECs induces colitis associated with increased colonic frequencies of innate
immune cells and expression of proinflammatory cytokines. CD4+ T-helper type (Th)1 cells - but not group 3 innate
lymphoid cells (ILCs) or Th17 cells - are elevated, resulting in an unfavourably altered ratio between CD4+ T cells and
forkhead box P3 (FoxP3)+ regulatory T (Treg) cells. IFN-c produced mainly by CD4+ T cells is required to upregulate MHCII
expression by IECs. These results suggest that, in addition to its proinflammatory roles, IFN-c exerts a critical anti-
inflammatory function in the intestine which protects against colitis by inducing MHCII expression on IECs. This may explain
the failure of anti-IFN-c treatment to induce remission in IBD patients, despite the association of elevated IFN-c and IBD.
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Introduction
IBDs are chronic and recurring inflammatory disorders
affecting the human gastrointestinal tract. There are two major
clinical forms of IBD, Crohn’s disease and ulcerative colitis.
Progression of Crohn’s disease is mainly driven by CD4+ Th1 and
Th17 cells, and IFN-c is a signature cytokine of the disease [1,2].
MHCII-mediated antigen presentation is fundamental for
driving CD4+ T cell orchestrated immune responses. MHCII is
primarily expressed on professional APCs, which induce both
effector T cell activation and FoxP3+ Treg cell-mediated tolerance
[3]. However, under inflammatory conditions, MHCII is typically
also induced on nonhematopoietic cells [4]. IECs are able to
process and present gut luminal antigens as they express the
MHCII antigen-presentation machinery and antigens in the
context of MHCII molecules [5,6,7,8,9,10]. However, as it
remains debated whether IECs are able to provide sufficient
costimulation for immunogenic T cell activation [11,12,13], it is
controversial whether their function as nonprofessional APCs
promotes CD4+ T cell-dependent tolerance or boosts immune
responses in situ. Previous observations obtained mainly from
in vitro or ex vivo studies might not reflect the more complex
situation in vivo [14,15,16].
Cell-type-specific expression of the MHCII antigen-presenta-
tion machinery is directed by the class II transactivator (CIITA).
CIITA expression is tightly regulated by the differential usage of
three independent promoters, pI, pIII and pIV [4]. pI is active in
myeloid cells. pIII activity is mainly restricted to lymphoid cells.
Importantly for this study, pIV2/2 mice display a selective
abrogation of inducible MHCII expression in nonhematopoietic
cells, including IECs. These mice lack positive selection of CD4+ T
cells due to the absence of MHCII on cortical thymic epithelial
cells (cTECs) [17]. However, CD4+ T cell development is restored
by introducing a CIITA transgene (Tg) driven by the keratin-14
(K14) promoter: The resulting pIV2/2 K14 CIITA Tg mice
harbour normal repertoires of CD4+ T cells and display normal
levels of MHCII on professional APCs, which depend on pI and
pIII, but lack inducible MHCII expression on nonhematopoietic
cells [4,17,18].
To investigate the in vivo role of nonhematopoietic MHCII
expression on the outcome of gut-specific immune responses and
pathology, we administered interleukin (IL)-10 receptor-blocking
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antibodies (anti-IL10R mAb) to pIV2/2 K14 CIITA Tg and
control mice infected chronically with H. hepaticus. In comparison
to the control mice, the absence of epithelial MHCII expression
led to colitis characterised by enhanced colonic infiltration of
innate effector cells and elevated expression of proinflammatory
chemokines and cytokines. This resulted in increased infiltration of
inflammatory CD4+ Th1 cells and an increased ratio between
CD4+ T cells and FoxP3+ Treg cells. A deficiency in IFN-c, or its
neutralization, resulted in the absence or reduced levels of
epithelial MHCII expression, respectively, suggesting that mainly
T cell-derived IFN-c is required to induce epithelial MHCII
expression. These findings reveal a critical role of IFN-c-induced
epithelial MHCII expression in contributing to intestinal homeo-
stasis by exerting an anti-inflammatory effect in vivo, which is
consistent with the failure to attenuate IBD with anti-IFN-c
treatment.
Materials and Methods
Animals
Mice were on a C57BL/6 background and were used between
6–10 weeks of age. pIV2/2 K14 CIITA Tg mice were described
previously [18]. C57BL/6 mice were obtained from Harlan
Laboratories. Heterozygous control mice were obtained by
crossing pIV2/2 K14 CIITA Tg with WT C57BL/6 mice.
pIVfl/fl vil-Cre Tg mice and pIVfl/fl littermates were generated by
crossing Vil-Cre-ERT2 mice [19] and pIVfl/fl mice [17]. Rag12/
2 IFN-c2/2 mice were obtained by crossing Rag12/2 mice
[20] and IFN-c2/2 mice [21]. Mice were housed in specific-
pathogen-free (SPF) facilities at the Universities of Lausanne or
Bern. All experiments were approved by the institutional, Swiss
federal and cantonal veterinary authorities (Permit number
1521.3), and all efforts were made to minimise suffering.
Anti-IL-10R mAb-induced Colitis Model
Experimental mice were obtained from H. hepaticus infected
parents. Prior and during in vivo experiments, the intestinal flora of
mice was synchronized by repeatedly exchanging feces among
experimental groups. Comparable H. hepaticus loads in individual
mice were confirmed by qPCR (details in Methods S1). Mice were
treated i.p. with 0.5 mg per injection of mAb 1B1.3a (anti–IL-
10R), or isotype control mAb Y13-259 (anti-p21 Ras Epitope
within amino acids 62–76), in PBS on days 0, 4, 7, 11, 14, 18, 21,
and 25. For in vivo IFN-c neutralization, mice were treated i.p.
with 400 mg per injection of mAb XMG1.2 (anti-IFN-c), or
isotype control mAb Y13-259, in PBS on days 11, 14, 18, 21, 25,
and 28. Weight of mice was followed daily during treatment until
day 28. Mice were sacrificed for analysis 1 wk after the last anti-
IL-10R mAb injection.
CD4+ T-cell Transfer Colitis Model
Colitis was induced by adoptive transfer of 26105 CD4+
CD252 CD45RBhi FACS-sorted T cells from WT or IFN-c2/2
mice into Rag12/2 or Rag12/2 IFN-c2/2 mice. Animals
were sacrificed at days 21–26 post CD4+ T cell transfer at the
onset of severe clinical signs of colitis (diarrhoea, severe weight
loss).
Colon Histopathological Analysis
Intestinal tissues of the mid-colon were immediately frozen in
Tissue-Tek O.C.T. compound (Sakura). 4–5 mm cross-sections
were stained with hematoxylin and eosin, and inflammation was
assessed blinded by a clinical pathologist on a scale of 0–15
according to the following criteria: Presence of lymphocyte
infiltration in the mucosa (0–1 score), submucosa (0–1 score)
and/or muscularis propia (0–1 score), cryptitis (0–3 score),
ulceration (0–3 score), crypt erosion/destruction (0–3 score). The
degree of inflammation was graded semi-quantitatively from 0 to 3
as follows: 0, no evidence of inflammation; 1, mild inflammation;
2, moderate inflammation; 3, severe inflammation. Microscopic
images were acquired using a DFC295 camera connected to a
DMIL LED light microscope via the FireCam Software (Leica
Microsystems).
Detection of Fecal Serum Albumin
Fresh feces were collected, lyophilized, and suspended in PBS.
Fecal albumin levels were determined using the ‘‘Mouse albumin
ELISA kit’’ (Bethyl Laboratories).
Cell Preparations and Purifications
Single cell suspensions from colonic epithelial and lamina
propria tissue fractions were obtained using a modification of an
established protocol [22]. Briefly, longitudinally-cut colon samples
were washed in PBS, further cut into small pieces, and incubated
twice in Hank’s balanced-salt solution (HBSS) containing 5 mM
EDTA and 2 mM DTT in a shaking incubator (37uC, 220 rpm)
for 30 minutes to isolate cells from the intestinal epithelium. To
derive lamina propria mononuclear cells, the tissue was further
incubated in HBSS containing 0.1 U/mL collagenase D and
50 U/mL DNase I (both Roche) in a shaking incubator (37uC,
220 rpm) for 2–3 cycles of 30–40 minutes. After each incubation
cycle, the collected fraction was sequentially filtered through a
70 mm and 40 mm cell strainer (BD Biosciences). For eventual
further enrichment of lymphocytes via gradient centrifugation,
derived cell fractions were resuspended in 40% Percoll (v/v) (GE
Healthcare), layered on top of 80% Percoll (v/v) and centrifuged
for 20 min at 10006g at RT. Lymphocytes were recovered at the
40%/80% Percoll interphase. Single cell suspensions from
lymphoid organs were obtained by mashing the organs through
a 40 mm cell strainer.
Flow Cytometry
Single cell suspensions were incubated with anti-FccRII/III
(2.4G2). The following antibodies (clones) were used for surface
staining: anti-CD3e (145-2C11), anti-CD4 (RM4-5), anti-CD8
(53-6.7), anti-CD11b (M1/70), anti-CD11c (N418), anti-CD25
(PC61.5), anti-CD40 (1C10), anti-CD44 (IM7), anti-CD45.2 (104),
anti-CD62L (MEL-14), anti-CD90.2 (53-2.1), anti-Ly-6C
(HK1.4), anti-Sca-1 (D7), anti-EpCAM (G8.8) (all from
eBioscience), anti-CD80 (16-10A1), anti-CD86 (GL-1), anti-
MHCII (M5/114.15.2), anti-Ly-6G (1A8) (all from Biolegend).
Dead cells were excluded by eF506 viability staining. For
transcription factor staining, cells were fixed and permeabilized
using the transcription factor staining kit and were stained with
anti-FoxP3 (FJK-16s) (both eBioscience). Samples were measured
on an LSR II flow cytometer (BD Biosciences), and analysed via
the FlowJo software (Tree Star).
qPCR
Small colonic explants were shock frozen in liquid nitrogen
before homogenisation using the Tissue Lyser II. RNA was
isolated by the RNeasy mini kit (both Qiagen). cDNA was
generated with the Superscript II reverse transcriptase kit (Life
Technologies) and random nonamer primers. cDNA concentra-
tions were adjusted and qPCR reactions were performed using the
SYBR Green Master Mix (Roche) on a LightCycler 480 machine
(Roche). The following primer sequences were used (from 59 to 39):
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ccl3 forward CCAAGTCTTCTCAGCGCCAT, reverse
TCCGGCTGTAGGAGAAGCAG; ccl4 forward
TCTTGCTCGTGGCTGCCT, reverse GGGAGGGTCA-
GAGCCCA; ccl5 forward CCTCACCATCATCCTCACTGC,
reverse TCTTCTCTGGGTTGGCACACA; ifn-g forward
GGATGCATTCATGAGTATTG, reverse
CTTTTCCGCTTCCTGAGG; il-1b forward CAACCAA-
CAAGTGATATTCTCCATG, reverse
GTGCCGTCTTTCATTACACAG; il-6 forward GAGGA-
TACCCTCCCAACAGACC, reverse AAGTGCAT-
CATCGTTGTTCATACA; Il-23p19 forward AGCGGGACA-
TATGAATCTACTAAGAGA, reverse
GTCCTAGTAGGGAGGTGTGAAGTTG; t-bet forward CAA-
CAACCCCTTTGCCAAAG, and reverse TCCCCCAAG-
CAGTTGACAGT; ror-ct forward CCGCTGAGAGGGCTT-
CAC, and reverse TGCAGGAGTAGGCCACATTACA; tbp
forward CCTTCACCAATGACTCCTATGAC, reverse
CAAGTTTACAGCCAAGATTCAC; b-actin forward GCA-
CAGCTTCTTTGCAGCTCCTTCG, reverse TTTGCA-
CATGCCGGAGCCGTTG. Gene expression for each individual
sample was normalised to the housekeeping genes TBP and b-
actin via the qBASE PLUS software (Biogazelle).
Detection of Secreted Cytokines in Colon Explants
Longitudinally-cut specimens of the mid-colon were rinsed with
PBS and cultured for 6 h in IMDM +10% FCS +561025 M 2-
ME at 37uC, 5% CO2. Debris was removed by centrifugation.
IFN-c (BD Biosciences) and IL-17A (eBioscience) were measured
by ELISA. All other molecules were detected using the Mouse
cytokine 20-Plex (Life Technologies) on a Luminex xMAP
analyser (Merck Millipore). Concentrations were normalized to
the weight of the colon explants.
Statistical Analysis
Differences in weight gain between groups of mice were assessed
by a repeated two-way analysis of variance (ANOVA), followed by
a Bonferroni post-hoc test. For all other experiments, differences
between groups were determined by the student’s unpaired t test
or, when the normality test failed, by the Mann-Whitney Rank
Sum test. P values are indicated when considered statistically
significant (*P,0.05, **P,0.01, and ***P,0.001).
Results
Characterisation of T cells in pIV2/2 K14 CIITA Tg Mice
It was previously shown that pIV2/2 K14 CIITA Tg mice are
deficient in nonhematopoietic MHCII expression but harbour
normal thymic and peripheral CD4+ T cell populations displaying
WT T cell receptor Vb-chain repertoires [18]. Frequencies of
CD4+ T cells, including FoxP3+ Treg cells, in colon-draining
mesenteric and caudal lymph nodes, the colonic intestinal
epithelium (cIE) and lamina propria (cLP) were found to be
comparable between pIV2/2 K14 CIITA Tg, heterozygous and
WT mice (Figure S1). We also observed a normal distribution of
CD4+ effector, memory, naı¨ve and FoxP3+ T cell subsets in the
thymus, spleen and peripheral lymph nodes (Figure S2). Finally,
we examined CD4+ T cell-dependent B cell responses in vivo in
pIV2/2 K14 CIITA Tg mice upon immunisation with 4-
Hydroxy-3-nitrophenylacetyl-hapten-23-conjugated chicken c-
globulin (NP23-CGG) or ovalbumin. Systemic antigen-specific
antibody responses in pIV2/2 K14 CIITA Tg mice were
comparable to WT mice (Figure S3). In line, affinity maturation,
assessed by detection of NP4-specific total serum IgG in NP23-
CGG immunised mice, was similar to WT mice (Figure S3A).
These results confirm that the phenotypes and functions of CD4+
T cells, including FoxP3+ Treg cells, in the colon and in primary
and secondary lymphoid organs of pIV2/2 K14 CIITA Tg mice
are comparable to those of WT mice.
Anti-IL-10R mAb Treatment during Chronic H. hepaticus
Infection in the Absence of Inducible Nonhematopoietic
MHCII Expression Leads to Colitis
To assess susceptibility to bacterial-driven intestinal inflamma-
tion, experimental mice chronically infected since birth with H.
hepaticus were treated with anti-IL-10R mAb. Prior and during the
treatment period, we synchronized the microbiome by repeatedly
exchanging feces among mice, based on the recent observation
that co-housed mice adopt each others’ microbial configuration in
the fecal content [23,24]. In addition, the low to undetectable
colonic MHCII expression in the steady state (shown below)
should not influence the flora. Notably, H. hepaticus loads were
comparable in all experimental mice before and after anti-IL10R
mAb treatment (Figure S4). It is important to mention that this
experimental system is different from the previously published
colitis model based on induction of chronic colitis by acute H.
hepaticus infection [25]. In contrast, in our setting, chronically
infected WT mice should not develop colitis.
To evaluate whether the absence of inducible nonhematopoietic
MHCII expression (shown below) alters susceptibility to bacterial-
driven colitis, pIV2/2 K14 CIITA Tg mice and heterozygous
controls chronically infected since birth with H. hepaticus were
treated with anti-IL-10R mAb. In contrast to MHCII-competent
controls, pIV2/2 K14 CIITA Tg mice gained significantly less
weight (Figure 1A), displayed significantly elevated fecal serum
albumin levels reflecting augmented protein-losing enteropathy
(Figure 1B), and developed a mild but prominent diarrhoea that
was not observed in heterozygous control mice (not shown).
Histopathological examinations of colon sections revealed an
exacerbated inflammation in pIV2/2 K14 CIITA Tg mice
(Figures 1C–D). pIV2/2 K14 CIITA Tg mice exhibited a diffuse
colonic mononuclear cell infiltration, whereas heterozygous
controls displayed only focal infiltration (not shown).
We next used a conditional knockout system to determine
whether the observed pathology is due to the lack of inducible
MHCII expression on IECs. Mice in which pIV is flanked by loxP
sites (pIVfl/fl) were crossed with mice harbouring a transgene in
which expression of tamoxifen-inducible Cre-recombinase is
controlled by an IEC-specific villin promoter (vil-Cre Tg). In
pIVfl/fl vil-Cre Tg mice, tamoxifen induces pIV excision
exclusively in IECs. Upon the administration of tamoxifen and
anti-IL-10R mAb pIVfl/fl vil-Cre Tg mice displayed increased
colitis susceptibility (Figures S5A–C), indicating that the absence of
inducible MHCII expression specifically on IECs significantly
exacerbates chronic H. hepaticus-mediated colitis. However, we
noted that tamoxifen altered the homeostatic composition of gut
lymphocytes (not shown) and affected colitis in control mice. This
is consistent with the fact that tamoxifen substantially affects the
murine gastrointestinal tract [26,27]. Due to the adverse effects of
tamoxifen we focussed on the constitutively pIV-depleted mice for
further experiments.
Colitic pIV2/2 K14 CIITA Tg Mice Display Increased
Innate Effector Cell Infiltration and Elevated Expression of
Proinflammatory Chemokines and Cytokines
We next sought to identify the major cellular and molecular
players mediating exacerbated inflammation and tissue damage in
colitic pIV2/2 K14 CIITA Tg mice. Infiltration of Ly6G+
Colitis in Absence of Epithelial MHCII
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neutrophils was increased in the colons of colitic pIV2/2 K14
CIITA Tg mice, which was significant in the cIE but not the cLP
(Figure 2A). CD11b+ Ly6C+ inflammatory monocytes were
significantly elevated in both the cIE and cLP (Figure 2B). These
innate effector cell subsets are also augmented in IBD patients [2].
We also noted a mild increase in CD11c+ DCs in the inflamed
colons (Figure S6). mRNA quantification revealed a significant
elevation of mRNAs encoding the proinflammatory chemokines
CCL3, CCL4 and CCL5 in the colons of colitic pIV2/2 K14
CIITA Tg mice (Figure 2C). These chemokines recruit innate
effector cells and T cells to sites of inflammation [28]. Moreover,
mRNAs encoding the inflammatory cytokines IL-1b and IL-6
were significantly increased (Figure 2C). We also found enhanced
colonic secretion of proinflammatory IL-1b, tumour necrosis
factor (TNF)-a and IL-12p40, as well as CXCL9 and vascular
endothelial growth factor (VEGF) in colitic pIV2/2 K14 CIITA
Tg mice (Figure 2D). Increased expression of IL-1b, TNF-a, IL-6
and IL-12p40 was previously observed in IBD patients [1,2].
CXCL9 secreted by innate effector cells was shown to promote T
cell activation and recruitment [29]. VEGF is known to increase
vascular permeability and inflammatory leukocyte extravasation in
IBD and experimental colitis [30]. In summary, the cellular and
molecular mediators of intestinal inflammation in colitic pIV2/2
K14 CIITA Tg mice display similarities to those in IBD,
underlining the physiological relevance of the applied colitis
model.
Exacerbated Colitis in pIV2/2 K14 CIITA Tg Mice
Correlates with the Inability of IECs to Upregulate MHCII
Expression
We next examined whether exacerbated colitis in pIV2/2
K14 CIITA Tg mice correlates with the loss of inducible MHCII
expression by IECs. IECs in anti-IL-10R-treated heterozygous
control mice upregulated MHCII expression, while this was not
observed in colitic pIV2/2 K14 CIITA Tg mice or healthy
isotype-treated controls (Figure 3). The same was true in the
inducible IEC-specific MHCII knock-out system (Figure S5D).
Confocal microscopy revealed that IECs from anti-IL-10R-treated
heterozygous mice expressed MHCII molecules on the basolateral
and apical surface (Figure S7). Since the provision of costimulation
by APCs is a prerequisite for immunogenic T cell activation, we
Figure 1. Chronic H. hepaticus infection plus anti-IL10R mAb treatment induces colitis in pIV2/2 K14 CIITA Tg mice. (A) Development
of body weight during anti-IL-10R mAb or isotype treatment of H. hepaticus-infected pIV2/2 K14 CIITA Tg mice or pIV+/2 K14 CIITA Tg controls
(n= 9–11 per group). (B) Serum albumin concentrations in feces collected on days 26–30 (n= 6–8 per group). Data are shown as mean and s.d. and
represent two pooled experiments. (C–D) Colon histopathological analysis on day 32; (C) colitis scores, data displayed as mean, and (D) representative
photomicrographs of colon sections, stained with hematoxylin and eosin. Bar, 100 mm. Data represent three pooled experiments (n= 9–11 per
group). aIL10R, anti-interleukin-10 receptor monoclonal antibodies;
doi:10.1371/journal.pone.0086844.g001
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examined whether IECs express costimulatory molecules in
healthy and/or colitic mice. We did not detect induction of the
classical costimulatory molecules CD40, CD80 and CD86 (Figure
S8). Collectively, these results confirm that exacerbated colitis in
pIV2/2 K14 CIITA Tg mice correlates with the inability of
IECs to express MHCII.
Colitic pIV2/2 K14 CIITA Tg Mice Display Elevated
Frequencies of Colonic CD4+ Th1 Cells and an Increased
CD4+ T cell: FoxP3+ Treg Cell Ratio
We next investigated the impact of deficient epithelial MHCII
expression on intestinal T cells during colitis. We observed an
increase in colonic CD4+ but not CD8+ T cells in colitic pIV2/2
K14 CIITA Tg mice, which was significant in the cIE but not the
cLP (Figures 4A–B). Colitic heterozygous mice only displayed a
mild elevation of CD4+ T cells. Similarly, CD4+ T cells were
significantly elevated in colitic pIVfl/fl vil-Cre Tg mice, which lack
MHCII expression specifically on IECs (Figure S5E). Examination
of T cell polarization revealed significantly augmented expression
of mRNAs encoding the Th1 signature factors T-bet and IFN-c,
as well as IFN-c secretion, in inflamed colons of pIV2/2 K14
CIITA Tg mice (Figures 4C–D).
Natural cytotoxicity-triggering receptor (NCR2) group 3 innate
lymphoid cells (ILC) cells were recently identified as important
cellular mediators of H. hepaticus-driven innate colitis [31,32].
However, we did neither detect a specific increase in these cells
(Figure S6B) nor in the expression of ror-ct, il23p19 or IL-17A,
which are diagnostic for group 3 ILCs and Th17 responses (Figure
S9). Thus, although we do not exclude a contribution of these cells
to the inflammatory process, they are unlikely to play a dominant
role in the increased pathology observed in our system.
Interestingly, we observed that colonic CD4+ T cells from colitic
pIV2/2 K14 CIITA Tg mice displayed a mildly reduced
expression of the co-inhibitory marker programmed cell death
(PD)-1 when compared to heterozygous mice (not shown). We also
found a significantly increased CD4+ T cell: FoxP3+ Treg cell ratio
in the cIE of colitic pIV2/2 K14 CIITA Tg mice compared to
identically treated heterozygous control mice (Figure 4E). The
majority of FoxP3+ cells lacked neuropillin (Nrp)-1 expression in
both anti-IL-10R-treated groups (not shown), suggesting that the
Figure 2. Innate effector cells and proinflammatory cytokines are elevated in colitic pIV2/2 K14 CIITA Tg mice. (A–B) Frequency of
Ly6G+ neutrophil granulocytes (A) and CD11b+ Ly6C+ inflammatory monocytes (B) isolated from the colonic intestinal epithelium (cIE, left panel) and
the colonic lamina propria (cLP, right panel) of H. hepaticus-infected pIV2/2 K14 CIITA Tg mice or pIV+/2 K14 CIITA Tg controls. (C) ccl3, ccl4, ccl5,
il1b and il6 mRNA expression levels in colon explants. (D) IL-1b, TNF-a, IL-12p40, CXCL9 and VEGF secretion upon ex vivo organ culture of colon
explants. All data represent three pooled experiments (n= 9–11 per group). aIL10R, anti-interleukin-10 receptor monoclonal antibodies; IL,
interleukin; TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor;
doi:10.1371/journal.pone.0086844.g002
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majority of colonic Treg cells were generated peripherally [33].
Taken together, these results indicate that MHCII expression by
IECs attenuates bacterial-driven colitis by preventing exacerbated
effector Th1 cell accumulation and the establishment of an
unfavourably altered ratio between conventional CD4+ T cells and
FoxP3+ Treg cells.
Epithelial MHCII Expression is Induced by IFN-c Mainly
Derived from CD4+ T cells
To examine whether IFN-c is responsible for inducing epithelial
MHCII expression we made use of the adoptive transfer colitis
model in which lymphocyte-deficient mice develop colitis upon
transfer of CD4+ CD45RBhi T cells [34]. Transfer of WT CD4+ T
cells into Rag12/2 IFN-c2/2 mice resulted in prominent
upregulation of epithelial MHCII expression, which was markedly
reduced when IFN-c2/2 CD4+ T cells were transferred into
IFN-c-competent Rag12/2 mice (Figure 5A). Notably, IECs did
not upregulate MHCII expression when both donor and recipient
mice lacked IFN-c (Figure 5A). Importantly, all experimental
groups developed severe colitis as assessed by histopathology
(Brasseit et al., manuscript in preparation). These results indicate
that IFN-c is the major cytokine driving MHCII expression on
IECs during adoptive transfer colitis, and that CD4+ T cells
represent the major source of IFN-c in this process.
To evaluate whether IFN-c-induced epithelial MHCII expres-
sion protects against colitis we administered neutralizing anti-IFN-
c mAb to pIV+/2 K14 CIITA Tg mice 11 days after initial anti-
IL-10R treatment to avoid interference with T cell polarization.
Neutralization of IFN-c in anti-IL-10R-treated pIV+/2 K14
CIITA Tg mice reduced MHCII expression by IECs as compared
to isotype-treated mice (Figure 5B). Importantly, this resulted in
elevated frequencies of CD4+ T cells in the cIE of anti-IFN-c
mAb-treated mice, comparable to pIV2/2 K14 CIITA Tg mice
(Figure 5C). In addition, preliminary data indicates that the CD4+
T cell: FoxP3+ Treg cell ratio is mildly elevated in anti-IFN-c-
administered pIV+/2 K14 CIITA Tg mice compared to isotype-
treated mice (not shown). Collectively, these findings suggest that
IFN-c-mediated MHCII expression by IECs plays an anti-
inflammatory role by reducing the accumulation of colitogenic
CD4+ T cells during chronic bacterial-driven colitis.
Discussion
We report here that the abrogation of inducible MHCII
expression on IECs during chronic H. hepaticus infection and anti-
IL-10R mAb treatment leads to overt colitis associated with an
augmented accumulation of CD4+ Th1 cells and an increased
CD4+ T cell:FoxP3+ Treg cell ratio. In contrast, heterozygous
control mice do not develop intestinal pathology as assessed by
clinical parameters, despite the fact that they display increased
MHCII expression by IECs and exhibit mildly elevated levels of
infiltrating CD4+ T cells. Finally, we show that epithelial MHCII
expression is induced by IFN-c produced mainly by CD4+ T cells.
We also examined whether NCR2 group 3 ILCs - which were
recently described to have a major role in murine innate colitis
[31,32] - or Th17 cells might be responsible for promoting
intestinal inflammation in the absence of nonhematopoietic
MHCII. However, we observed comparable group 3 ILC
frequencies in all anti-IL-10R mAb-administered animal groups,
and no increase in associated factors ROR-ct, IL-23 and IL-17A.
Thus, albeit group 3 ILCs and Th17 cells may play an important
role in colitis, we exclude a decisive role in determining disease
severity in our model.
Induction of MHCII on IECs correlated with a protection
against colitis in heterozygous mice, indicating that the low-levels
of IFN-c observed in heterozygous mice were sufficient to
maintain intestinal homeostasis via the upregulation of MHCII
expression during chronic H. hepaticus infection and anti-IL-10R
treatment. IECs are well known to fulfil diverse functions crucial
for intestinal homeostasis, including the capacity to modulate
intestinal immune responses [3]. Here we expand these previous
findings by reporting an MHCII-dependent anti-inflammatory
role of IECs that confers protection against colitis induced by
chronic H. hepaticus colonization.
Previous studies examining potential antigen-presentation func-
tions of IECs and their consequences for intestinal inflammation
generated conflicting results and relied almost exclusively on
in vitro or ex vivo assays [14,15,16]. One recent in vivo study using a
mouse model in which MHCII is expressed solely on IECs
indicated that antigen presentation by bone marrow-derived APCs
is indispensable for triggering severe bacterial-driven intestinal
pathology [35].
Immunogenic T cell activation requires TCR-MHCII-depen-
dent signals, the presence of polarizing cytokines and the provision
of costimulation. Whether IECs can express classical costimulatory
molecules remains a matter of debate [11,12,13]. In our model we
did not observe expression of the classical costimulatory molecules
CD40, CD80 or CD86 on MHCII+ IECs. Antigen-presentation in
Figure 3. Colitic pIV2/2 K14 CIITA Tg mice lack inducible
MHCII expression by colonic IECs. (A–B) Frequency of CD45.22
EpCAM+ MHCII+ IECs isolated from anti-IL-10R mAb or isotype treated,
H. hepaticus-infected pIV2/2 K14 CIITA Tg mice or pIV+/2 K14 CIITA Tg
controls. Representative histograms (A) and summarized data as mean
(B) from three pooled experiments (n= 8–11 per group). aIL10R, anti-
interleukin-10 receptor monoclonal antibodies; IEC, intestinal epithelial
cell;
doi:10.1371/journal.pone.0086844.g003
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the absence of costimulatory molecules has been proposed to limit
CD4+ T cell responses [36], which is consistent with the finding
that IECs are not bona fide professional APCs capable of promoting
severe colitis in vivo [35]. However, non-classical costimulatory
molecules, such as IcosL, PD-L1 or LFA3 have been proposed to
be used by IECs to interact with CD4+ T cells [12,37].
The anti-inflammatory cytokine IL-10 is critical for maintaining
local tissue homeostasis in the presence of intestinal H. hepaticus
infection. First indications for this came from early observations in
IL-10-deficient mice that developed spontaneous colitis under
conventional housing conditions which was significantly less severe
(or even absent) when mice were held under SPF conditions [38].
Deliberate infection of SPF-housed IL-102/2 mice with H.
hepaticus significantly exacerbated the development of colitis [39],
and susceptibility to colitis induction is re-established in WT mice,
treated with anti-IL-10R mAb following H. hepaticus infection [25].
Figure 4. Colitic pIV2/2 K14 CIITA Tg mice display elevated Th1 cells, IFN-c, and CD4+ T cell: FoxP3+ Treg cell ratios. (A–B) Frequency
of CD3+ CD4+ and CD8+ T cells isolated from anti-IL-10R mAb or isotype treated, H. hepaticus-infected pIV2/2 K14 CIITA Tg mice or pIV+/2 K14 CIITA
Tg controls. Representative histograms from the colonic intestinal epithelium (cIE) (A) and summarized data (B) from cIE (left) and the colonic lamina
propria (cLP) (right) as mean. (C) ifng and tbet mRNA expression levels in colon explants. (D) IFN-c secretion upon ex vivo organ culture of colon
explants as means and s.d. (A–D) Data represent three pooled experiments (n= 9–11 per group). (E) Ratio of absolute numbers of CD4+ T
cells:absolute numbers of CD25+ FoxP3+ Treg cells from cIE (left) and cLP (right) as mean from two pooled experiments (n= 7–10 per group). aIL10R,
anti-interleukin-10 receptor monoclonal antibodies; FoxP3, forkhead box P3; IFN, interferon;
doi:10.1371/journal.pone.0086844.g004
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Furthermore, H. hepaticus was shown to induce colitis in
lymphocyte-deficient 129/SvEv Rag22/2 mice [32,40,41].
However, adoptive transfer of Treg cells inhibits the development
of gut inflammation in this colitis model [41,42,43], which
depends on the ability of transferred cells to express IL-10
[43,44]. Similarly, IL-10 is important to prevent colitis in humans,
as certain variants of early-onset IBD observed in infants and small
children appear to be a monogenic diseases caused by deleting
mutations in IL-10 or its receptor (reviewed in [45]).
In contrast, the complex role of IFN-c during H. hepaticus-
induced colitis is incompletely understood. Injection of IFN-c-
neutralizing mAb into H. hepaticus-infected IL-102/2 mice
suggested that IFN-c is required for disease onset but not for the
chronicity of colitis [39,46]. Similarly, H. hepaticus-infected IFN-
c2/2 mice treated with anti-IL-10R mAb developed less
intestinal inflammation than WT mice [25], suggesting a
contribution of IFN-c to colitis development. In contrast, the
severity of H. hepaticus-induced colitis in mice lacking both IL-10
and IFN-c was comparable to mice lacking IL-10 alone [46],
indicating that IFN-c does not favour colitis development.
Recently, it was reported that during the course of H. hepaticus-
mediated colitis, induced Th17 cells switch phenotype to become
IFN-c+ ex-Th17 cells [47]. These results imply A) the potential
existence of alternative pathways affecting colitis development
following acute H. hepaticus infection, e.g. via the increase of
inflammatory Th17 cells in the absence of IFN-c, and B) that IFN-
c may have both pro- and anti-inflammatory effects on the
outcome of H. hepaticus-mediated colitis [25]. Our results expand
these previous observations by demonstrating that IFN-c-mediated
upregulation of MHCII molecules on IECs plays an anti-
inflammatory role that reduces infiltrating CD4+ effector T cell
frequencies and avoids the establishment of a pathologically
altered CD4+ T cell:FoxP3+ Treg cell ratio in the colon. Of note,
IFN-c was reported to feature anti-inflammatory properties in the
context of oral tolerance [48].
Our findings may help to explain why anti-IFN-c treatments
have consistently failed to induce remission in patients with active
IBD despite the association of enhanced IFN-c expression with
IBD [49]. Moreover, this study paves the way for further work on
the MHCII-dependent tolerogenic function of IECs as a potential
therapeutic target in patients suffering from inflammatory
disorders of the intestine.
Supporting Information
Figure S1 Intestinal FoxP3+ Treg cell frequencies in
healthy pIV2/2 K14 CIITA Tgmice. (A–D) Healthy pIV2/
2 K14 CIITA Tg, pIV+/2 K14 CIITA Tg and C57BL/6 WT
mice were subjected to flow cytometry. (A) Mesenteric lymph node
(mLN), (B) caudal lymph node (cLN), (C) colonic intestinal
epithelium (cIE) and (D) colonic lamina propria (cLP) cells were
gated on CD45.2+ CD4+ cells, and from there on FoxP3+ cells.
Data shown represents mean and s.d. (n= 3 per group). FoxP3,
forkhead box P3; WT, wild type;
(TIF)
Figure S2 Lymphoid organ T cell frequencies in healthy
pIV2/2 K14 CIITA Tg mice. (A–C) Thymus (THY), spleen
(SPL) and pooled peripheral lymph nodes (LN) of healthy pIV2/
2 K14 CIITA Tg, pIV+/2 K14 CIITA Tg and C57/BL6 wild
type (WT) mice were subjected to flow cytometry. Dead cells were
excluded and CD3+ cells were gated on (A) CD4 and CD8. (B)
CD4+ CD82 T cells were gated on CD44 and CD62L to identify
effector (Teff, CD44
+ CD62L2), memory (Tmem, CD44
+ CD62L+)
and naı¨ve T (Tnaive, CD44
2 CD62L+) cells. (C) CD4+ T cells were
gated on CD25 and FoxP3. Data shown represents mean and s.d.
(n = 3 per group) from one experiment out of at least two
experiments.
(TIF)
Figure S3 Similar specific total IgG responses upon
exogenous antigen immunisation in pIV2/2 K14 CIITA
Tg mice. (A–B) pIV2/2 K14 CIITA Tg, pIV+/2 K14 CIITA
Tg and B6 WT mice were immunised with 4-Hydroxy-3-
nitrophenylacetyl hapten-conjugated chicken gamma globulin
(NP23-CGG) or ovalbumin. Serum was analysed for the presence
of antigen-specific total IgG against either (A) NP4 and (B)
ovalbumin. Data represent mean and s.d. (n = 7–8 per group) from
two pooled experiments. IgG, immunoglobulin G;
(TIF)
Figure S4 H. hepaticus colonization levels before and
after anti-IL-10R treatment. Fresh fecal specimens from
pIV2/2 K14 CIITA Tg and pIV+/2 K14 CIITA Tg mice were
Figure 5. IFN-c induces MHCII expression on IECs. (A) Frequency
of CD45.22 EpCAM+ MHCII+ intestinal epithelial cells (IEC) isolated from
Rag12/2 or Rag12/2 IFN-c2/2mice that were adoptively transferred
with CD4+ CD45RBhi T cells from WT or IFN-c2/2mice shown as means
and SEM in representative histograms (n= 3 mice per group). (B–C)
Frequency of CD45.22 EpCAM+ MHCII+ IECs (B) and CD4+ T cells from
the colonic intestinal epithelium (C) isolated from H. hepaticus-infected,
anti-IL-10R mAb-administered pIV2/2 K14 CIITA Tg, pIV+/2 K14 CIITA
Tg or pIV+/2 K14 CIITA Tg that were treated with neutralizing anti-IFN-
c mAb. Shown are representative FACS plots, means and SEM from two
pooled experiments (n=4–7 mice per group). aIFN-y, anti-interferon-c
monoclonal antibodies; FSC, forward scatter; IFN, interferon; Rag,
recombination activating gene; WT, wild type;
doi:10.1371/journal.pone.0086844.g005
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collected on days 24 to 22 before anti-IL-10R administration,
and on days 26–28 of the experiment. Total fecal DNA was
isolated and H. hepaticus DNA was quantified by qPCR and
normalized to the dry weight of the fecal pellet. Each symbol
represents a single animal. aIL10R, anti-interleukin-10 receptor
monoclonal antibodies;
(TIF)
Figure S5 H. hepaticus infection plus anti-IL10R mAb
treatment induces exacerbated colitis in pIVfl/fl vil-Cre
Tg mice. (A) Development of body weight during anti-IL-10R
mAb or isotype treatment of H. hepaticus-infected, tamoxifen-
administered pIVfl/fl vil-Cre Tg mice or pIVfl/fl controls. Data are
shown as mean. (B) Serum albumin concentrations in feces
collected on days 26–30. Data are shown as mean and s.d. (C)
Colitis scores upon organ collection on day 32. Data displayed as
mean. (D) Frequency of CD45.22 EpCAM+ MHCII+ IECs.
Representative histograms (left) and summarized data (right) as
mean. (E) Frequency of CD3+ CD4+ and CD8+ T cells in the cIE.
Representative histograms (left) and summarized data (right) as
mean. All data represent n = 3–5 per group. aIL10R, anti-
interleukin-10 receptor monoclonal antibodies;
(TIF)
Figure S6 Levels of colonic DC and group 3 ILCs in
colitic pIV2/2 K14 CIITA Tg. (A) Frequency of Ly6C2
CD11c+ conventional DCs in the cIE and cLP and (B) CD45.2+
Lin2 (CD11b, Gr-1, B220) CD3e2 Thy1high Sca-1+ group 3 ILCs
in the cLP isolated from anti-IL-10R mAb or isotype treated, H.
hepaticus-infected pIV2/2 K14 CIITA Tg mice or pIV+/2 K14
CIITA Tg controls. (A) Representative histograms (left) display the
cIE and data (right) represent mean (n = 9–11 per group) from
three pooled experiments. (B) dot plots showed represent n = 3–
4 per group. aIL10R, anti-interleukin-10 receptor monoclonal
antibodies;
(TIF)
Figure S7 Colonic IECs from anti-IL-10R-treated pIV+/
2 K14 CIITA Tg mice express MHCII molecules apically
and basolaterally. (A and B) H. hepaticus-infected pIV2/2 K14
CIITA Tg or pIV+/2 K14 CIITA Tg control mice were treated
with anti-IL-10R mAb or isotype control mAb. Mid-colon sections
were stained with DAPI (blue) to label nuclei and anti-MHCII
mAb (red). (A) Representative pIV2/2 K14 CIITA Tg mouse
and (B) representative pIV+/2 K14 CIITA Tg mouse. Right
upper panel depicts a region with MHCII2 IECs; Right lower
panel depicts a region with MHCII+ IECs. Bar, 20 mm.
(TIF)
Figure S8 Colitic mice do not induce the expression of
CD40, CD80 and CD86 on colonic IECs. (A–C) CD45.22
EpCAM+ IECs isolated from anti-IL-10R mAb or isotype treated,
H. hepaticus-infected pIV2/2 K14 CIITA Tg mice or pIV+/2
K14 CIITA Tg controls were analysed for the expression of
classical costimulatory molecules by flow cytometry. (A) Frequency
of CD40, (B) CD80 or (C) CD86. Histograms represent n = 3–
5 per group. aIL10R, anti-interleukin-10 receptor monoclonal
antibodies;
(TIF)
Figure S9 Expression levels of Th17- and group 3 ILC-
associated factors. (A–B) H. hepaticus-infected pIV2/2 K14
CIITA Tg or pIV+/2 K14 CIITA Tg control mice were treated
with anti-IL-10R mAb or isotype control mAb. (A) ror-ct and
il23p19 mRNA expression levels in colon explants. Data represent
n = 9–11 per group from three pooled experiments. (B) IL-17A
secretion upon ex vivo organ culture of colon explants. Data
represent n = 6 per group from two pooled experiments. Data
displayed as mean and s.d. aIL10R, anti-interleukin-10 receptor
monoclonal antibodies;
(TIF)
Methods S1 Additional methods applied to generate
supporting figures.
(DOC)
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